Shots:
- Oncorus has initiated a P-I study assessing ONCR-177 as monothx. and in combination with Merck’s Keytruda in patients with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors
- The P-I study enrolls ~21 cancer patients while P-II study enrolls patients to histology- specific expansion cohorts. The P-I study will evaluate the safety and tolerability and determine the recommended P-II dose and as preliminary anti-tumor activity of ONCR-177 as monothx. & combination therapy
- The planned expansion cohorts will include patients with BC, SCCHN, and melanoma. ONCR-177 is an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy and is armed with oHSV, IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4 designed to stimulate multiple arms of the immune system
Click here to read full press release/ article | Ref: Oncorus | Image: Pitt Innovation System
